← Back to list
Announcement Details analyzed
ID
4164
Seq No
106569238
Symbol
MANGALAM
Company
Mangalam Drugs And Organics Limited
Subject
Change in Company Secretary/Compliance Officer
Category
Change in Company Secretary/Compliance Officer
Description
Mangalam Drugs And Organics Limited has informed the Exchange about Change in Company Secretary/Compliance Officer
Ann. Date
2026-03-26 13:02:10
Dissemination
26-Mar-2026 13:02:11
Attachment
📄 Download PDF MANGALAM_26032026130203_OUTCOME260326.pdf
Created
2026-03-26T07:34:22.238Z
Updated
2026-03-26T07:35:25.205Z
AI Analysis claude-cli
High Impact Event
Company
Mangalam Drugs and Organics Limited
Event
Resignation of Company Secretary Ms. Anuradha Pandey (effective 29 March 2026) and appointment of Ms. Shweta Patel as Company Secretary & Compliance Officer (effective 1 April 2026)
Time
March 26, 2026 (Board meeting: 12:00 PM – 12:40 PM)
Key Insight

The transition is orderly with no gap in compliance coverage — Pandey exits on 29 March and Patel assumes charge on 1 April 2026. Patel is an Associate Member of ICSI with 3 years of experience in listed and group company compliances. The resignation was tendered as early as 2 January 2026, suggesting the Board had ample time to arrange a successor.

Why it Matters

For a small-cap company (₹47 Cr market cap), continuity of the Compliance Officer role is operationally significant given regulatory obligations under SEBI LODR. The seamless handover reduces the risk of compliance lapses. Investor impact is minimal as this is a routine personnel change with no strategic or financial implications.

Market Cap
₹47.17 Cr
Sector
Pharmaceuticals & Specialty Chemicals
Source
NSE Corporate Announcement
Link
NSE Announcements
Confidence Score
3/10
High impact event
  - Company Name: Mangalam Drugs and Organics Limited
  - Event: Resignation of Company Secretary Ms. Anuradha Pandey (effective 29 March 2026) and appointment of Ms. Shweta Patel as Company Secretary & Compliance Officer (effective 1 April 2026)
  - Time: March 26, 2026 (Board meeting: 12:00 PM – 12:40 PM)

Key Insight: The transition is orderly with no gap in compliance coverage — Pandey exits on 29 March and Patel assumes charge on 1 April 2026. Patel is an Associate Member of ICSI with 3 years of experience in listed and group company compliances. The resignation was tendered as early as 2 January 2026, suggesting the Board had ample time to arrange a successor.

Why it matters: For a small-cap company (₹47 Cr market cap), continuity of the Compliance Officer role is operationally significant given regulatory obligations under SEBI LODR. The seamless handover reduces the risk of compliance lapses. Investor impact is minimal as this is a routine personnel change with no strategic or financial implications.

Market cap: ₹47.17 Cr
sector: Pharmaceuticals & Specialty Chemicals
confidence score: 3

Source: NSE Corporate Announcement
Link: https://www.nseindia.com/companies-listing/corporate-filings-announcements